Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine

Journal of Internal Medicine

Volumn 269, Issue 5, 2011, Pages 546-556

  Wigren, M ^a   Kolbus, D ^a   Duner P ^a   Ljungcrantz, I ^a   Soderberg I ^a   Bjorkbacka H ^a   Fredrikson, G N ^a,b   Nilsson, J ^a  

^a LUND UNIVERSITY   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

Author keywords

Apolipoprotein B; Atherosclerosis; Autoimmunity; Regulatory T cells; Vaccine

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B210; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; PEPTIDE VACCINE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CD25+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL;

ANIMALS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CELLS, CULTURED; CHOLESTEROL; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; SPLEEN; T-LYMPHOCYTES, REGULATORY; TRIGLYCERIDES; VACCINES, SUBUNIT;

EID: 79954576946     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02311.x     Document Type: Article

References (48)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8: 1218-26.
3. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-19.
4. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-81.
5. Tupin E, Nicoletti A, Elhage R et al. CD1d-dependent Activation of NKT Cells Aggravates Atherosclerosis. J Exp Med 2004; 199: 417-22.
6. Niwa T, Wada H, Ohashi H et al. Interferon-gamma produced by bone marrow-derived cells attenuates atherosclerotic lesion formation in LDLR-deficient mice. J Atheroscler Thromb 2004; 11: 79-87.
7. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 2005; 102: 1596-601.
8. Kishikawa H, Shimokama T, Watanabe T. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis. Virchows Arch A Pathol Anat Histopathol 1993; 423: 433-42.
9. van derWalAC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989; 61: 166-70.
10. Yilmaz A, Lochno M, Traeg F et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004; 176: 101-10.
11. Liuzzo G, Goronzy JJ, Yang H et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-8.
12. Paulsson G, Zhou X, Tornquist E, Hansson GK. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 10-7.
13. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995; 92: 3893-7.
14. Zhou X, Robertson AK, Hjerpe C, Hansson GK. Adoptive Transfer of CD4+ T Cells Reactive to Modified Low-Density Lipoprotein Aggravates Atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 864-70.
15. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 1995; 92: 821-5.
16. Ameli S, Hultgardh-Nilsson A, Regnstrom J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-9.
17. George J, Afek A, Gilburd B et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-52.
18. Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 108-14.
19. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005; 25: 18-28.
20. Shah PK, Chyu KY, Fredrikson GN, Nilsson J. Immunomodulation of atherosclerosis with a vaccine. Nat Clin Pract Cardiovasc Med 2005; 2: 639-46.
21. Fredrikson GN, Hedblad B, Berglund G et al. Identification of immune responses against aldehyde-modified peptide sequences in apo B-100 associated with cardiovascular disease. Arterioscler Thromb Vasc Biol 2003; 23: 872-8.
22. Fredrikson GN, Soderberg I, Lindholm M et al. Inhibition of atherosclerosis in ApoE-Null mice by immunization with ApoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 2003; 23: 879-84.
23. Chyu KY, Zhao X, Reyes OS et al. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice. Biochem Biophys Res Commun 2005; 338: 1982-9.
24. Fredrikson GN, Andersson L, Soderberg I et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity 2005; 38: 171-9.
25. Schiopu A, Bengtsson J, Soderberg I et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004; 110: 2047-52.
26. Fredrikson GN, Bjorkbacka H, Soderberg I, Ljungcrantz I, Nilsson J. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J Intern Med 2008; 264: 563-70.
27. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101: 455-8.
28. Ait-Oufella H, Salomon BL, Potteaux S et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-80.
29. Mallat Z, Gojova A, Brun V et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003; 108: 1232-7.
30. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med 2007; 17: 113-8.
31. Wigren M, Bengtsson D, Duner P et al. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells. Circ Res 2009; 104: e62-70.
32. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-55.
33. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-61.
34. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 734-42.
35. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T cell responses: potential role in the control of atherosclerosis. Curr Opin Lipidol 2005; 16: 518-24.
36. Gotsman I, Grabie N, Gupta R et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006; 114: 2047-55.
37. Maron R, Sukhova G, Faria AM et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1708-15.
38. Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 2002; 40: 1333-8.
39. van Puijvelde GH, van Es T, van Wanrooij EJ et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T Cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2677-83.
40. van Puijvelde GH, Hauer AD, de Vos P et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006; 114: 1968-76.
41. Mor A, Planer D, Luboshits G et al. Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 893-900.
42. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE 2007; 2: e779.
43. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006; 212: 256-71.
44. Thoman ML, Weigle WO. Partial restoration of Con A-induced proliferation, IL-2 receptor expression, and IL-2 synthesis in aged murine lymphocytes by phorbol myristate acetate and ionomycin. Cell Immunol 1988; 114: 1-11.
45. Sardella G, De Luca L, Francavilla V et al. Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. Thromb Res 2007; 120: 631-4.
46. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-25.
47. Binder CJ, Hartvigsen K, Chang MK et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-37.
48. Khallou-Laschet J, Tupin E, Caligiuri G et al. Atheroprotective effect of adjuvants in apolipoprotein E knockout mice. Atherosclerosis 2006; 184: 330-41.